Actionable news
0
All posts from Actionable news
Actionable news in MIRN: Mirna Therapeutics Inc,

Mirna Therapeutics Presents Interim Phase 1 Data on First-in-Class microRNA-34 mimic, MRX34, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics (Mirna), a private, clinical-stage biopharmaceutical company focused on the development of microRNA-based oncology therapeutics, today announced interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34. The data show that MRX34 has a manageable safety profile in patients with advanced primary liver cancer (hepatocellular carcinoma), other solid tumors with liver metastasis, and hematological malignancies. A maximum tolerated dose (MTD) was established at 110 mg/m2 for MRX34 administered twice weekly for three weeks followed by one week off. Dose escalation is on-going for a second dosing regimen wherein MRX34 is administered daily for five consecutive days followed by two weeks off. While this Phase 1 study is intended to investigate safety, tolerability, pharmacokinetics, and dosing regimens, treatment with MRX34 has provided early signals of clinical activity in advanced cancer patients with primary liver, neuroendocrine, colorectal and small cell lung cancers, as well as diffuse large B-cell lymphoma.

“As the first microRNA mimic to enter clinical development, the data reported today represent another step forward for MRX34, our lead product candidate”

The findings were presented by Muhammad Shaalan Beg, M.D., Assistant Professor of Internal Medicine and co-leader of the gastro-intestinal oncology group at University of Texas Southwestern Harold C. Simmons Cancer Center in Dallas, Texas, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association...


More